Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NBIX
#636
Neurocrine Biosciences, Inc. - Common Stock
174.1
0
USD
-0.02%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.70%
Monthly Change
+8.89%
6 month change
+28.73%
Year Change
+20.07%
Previous Close
177.1
1
Open
174.1
0
Low
174.1
0
High
174.1
0
Volume
110
Markets
US Stock Market
Healthcare
Drug Manufacturers—Specialty & Generic
NBIX
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
93.94 M
95.24 M
96.59 M
99.51 M
99.7 M
100.36 M
100.55 M
Valuation ratios
Enterprise value
9.14 B
8.11 B
11.5 B
12.86 B
13.38 B
13.52 B
17.86 B
Price to earnings ratio
23.04
92.58
76.97
53.33
41.49
30.37
27.73
Price to sales ratio
8.96
7.36
7.98
7.05
6.01
5.08
5.95
Price to cash flow ratio
41.02
32.51
34.99
34.12
23.77
18.57
21.38
Price to book ratio
8.32
6.07
6.95
5.96
5.47
4.47
1.49
Enterprise value to EBITDA ratio
47.33
62.02
43.28
50.5
19.16
21.24
21.9
Profitability ratios
Return on assets %
0.23
0.04
0.07
0.08
0.09
0.1
0.04
Return on equity %
0.36
0.07
0.09
0.11
0.13
0.15
0.06
Return on invested capital %
-142.41
38.13
64.21
51.06
79.5
67.84
23.44
Gross margin %
100
100
98.44
97.9
98.56
98.18
98.31
Operating margin %
15.58
9.04
16.73
13.3
24.22
21.64
23.74
EBITDA margin %
18.45
11.53
17.85
13.49
29.64
22.25
24.48
Net margin %
38.94
7.9
10.38
13.23
14.49
16.73
24.3
Liquidity ratios
Quick ratio
5.3
3.83
2.64
2.4
3.28
3.3
2.85
Current ratio
5.45
3.96
2.7
2.45
3.4
3.39
2.93
Inventory turnover
—
—
0.71
1.08
0.71
0.76
0.21
Asset turnover
0.69
0.6
0.67
0.67
0.68
0.62
0.17
Solvency ratios
Debt to assets ratio
0.18
0.16
0.07
—
—
—
—
Debt to equity ratio
0.28
0.24
0.1
—
—
—
—
Long term debt to total assets ratio
-0.04
-0.02
0.07
0.05
0
—
—
Long term debt to total equity ratio
-0.06
-0.03
0.1
0.08
0
—
—
Per share metrics
Operating cash flow per share
2.34
2.62
3.43
3.86
5.74
7.64
8.43
EBIT per share
1.67
1.05
2.52
2.48
5.5
6.04
7.7
EBITDA per share
1.97
1.34
2.69
2.52
6.73
6.21
7.96
Total debt per share
3.25
3.42
1.71
—
—
—
—
Cash per share
8.19
7.27
10
10.21
10.38
14.44
12.73
Net current asset value per share
10.39
9.94
14.7
15.91
16.63
24.61
23.56
Tangible book value per share
11.52
14.03
17.27
22.1
24.97
31.74
32.95
Working capital per share
8.48
7.43
9.26
9.43
11.74
17.36
15.52
Book value per share
11.52
14.03
17.27
22.1
24.97
31.74
32.95
News
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
Agilent Strengthens Biopharma Growth Prospects With AI Expansion
Three Enticing Clues Put This Broadcom Partner, Nvidia Rival In Focus
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Axsome Therapeutics, Exelixis, Incyte Among 20 New Stocks On IBD's Premier Watchlists
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Reasons Why Investors Should Consider Betting on Neurocrine Stock
GE Aerospace Hits Record High, Leads 19 Onto IBD 50, Big Cap 20, Other Best Stock Lists
Neurocrine Biosciences: Why I Am Upholding A Buy Rating After M&A Deal For Soleno (NBIX)